All In Biotech

Investigational drug · Phase 2

ONO-1110

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Fibromyalgia, Social Anxiety Disorder (SAD), Major Depressive Disorder (MDD.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

5

0 still active

All registered trials

5

Any phase or sponsor naming "ONO-1110"

First trial start

2025

Jan 16, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ONO-1110", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Fibromyalgia
  • Social Anxiety Disorder (SAD)
  • Major Depressive Disorder (MDD
  • Hunner Type Interstitial Cystitis
  • Postherpetic Neuralgia

Approved drugs for the same conditions: Neuropathic pain · Depression (major depressive disorder) · Anxiety disorders · Psychiatry

Largest trials

Live from ClinicalTrials.gov: studies naming "ONO-1110" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Fibromyalgia

  • AXS-14EsreboxetinePhase 32 trials

    Axsome Therapeutics, Inc. · Fibromyalgia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.